Nrf2/ARE signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS

Neurology Research International

Volumn 2012, Issue , 2012, Pages

  Petri, Susanne ^a   Körner, Sonja ^a   Kiaei, Mahmoud ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867320492     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2012/878030     Document Type: Review

References (53)

1. Rosen D. R., Siddique T., Patterson D., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 362 59 62 10.1038/362059a0 (Pubitemid 23087289)
2. Siddique T., Ajroud-Driss S., Familial amyotrophic lateral sclerosis, a historical perspective. Acta Myologica 2011 30 117 120 2-s2.0-81455128285
3. Wu C.-H., Fallini C., Ticozzi N., Keagle P. J., Sapp P. C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D. M., Kost J. E., Gonzalez-Perez P., Fox A. D., Adams J., Taroni F., Tiloca C., Leclerc A. L., Chafe S. C., Mangroo D., Moore M. J., Zitzewitz J. A., Xu Z.-S., Van Den Berg L. H., Glass J. D., Siciliano G., Cirulli E. T., Goldstein D. B., Salachas F., Meininger V., Rossoll W., Ratti A., Gellera C., Bosco D. A., Bassell G. J., Silani V., Drory V. E., Brown R. H. Jr., Landers J. E., Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012 488 7412 499 503 2-s2.0-84865235172 10.1038/nature11280
4. Contestabile A., Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Current Medicinal Chemistry 2011 18 36 5655 5665 2-s2.0-84055192382
5. Gurney M. E., Pu H., Chiu A. Y., Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994 264 1772 1775 10.1126/science.8209258 (Pubitemid 24227760)
6. Aguirre N., Beal M. F., Matson W. R., Bogdanov M. B., Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radical Research 2005 39 4 383 388 2-s2.0-18144387600 10.1080/10715760400027979 (Pubitemid 40613717)
7. Beal M. F., Ferrante R. J., Browne S. E., Matthews R. T., Kowall N. W., Brown R. H., Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology 1997 42 4 644 654 2-s2.0-0030851761 10.1002/ana.410420416 (Pubitemid 27439028)
8. Ferrante R. J., Shinobu L. A., Schulz J. B., Matthews R. T., Thomas C. E., Kowall N. W., Gurney M. E., Flint Beal M., Increased 3-Nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology 1997 42 3 326 334 2-s2.0-0030767498 10.1002/ana.410420309 (Pubitemid 27391116)
9. Perluigi M., Poon H. F., Hensley K., Pierce W. M., Klein J. B., Calabrese V., De Marco C., Butterfield D. A., Proteomic analysis of 4-hydroxy-2-nonenal- modified proteins in G93A-SOD1 transgenic micea model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2005 38 7 960 968 2-s2.0-14644400490 10.1016/j.freeradbiomed.2004.12.021 (Pubitemid 40321087)
10. Orrell R. W., Lane R. J., Ross M., Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews (Online) 2007 1, article CD002829 2-s2.0-34247873012
11. Sun G. Y., Horrocks L. A., Farooqui A. A., The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. Journal of Neurochemistry 2007 103 1 1 16 2-s2.0-34548121631 10.1111/j.1471-4159.2007.04670.x (Pubitemid 47404193)
12. Zhang H., Liu H., Davies K. J. A., Sioutas C., Finch C. E., Morgan T. E., Forman H. J., Nrf2-regulated phase II enzymes are induced by chronic ambient nanoparticle exposure in young mice with age-related impairments. Free Radical Biology and Medicine 2012 52 9 2038 2046 2-s2.0-84860471609 10.1016/j. freeradbiomed.2012.02.042
13. van Muiswinkel F. L., Kuiperij H. B., The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Current Drug Targets 2005 4 3 267 281 2-s2.0-19944384264 10.2174/ 1568007054038238 (Pubitemid 40754162)
14. Shih A. Y., Imbeault S., Barakauskas V., Erb H., Jiang L., Li P., Murphy T. H., Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. The Journal of Biological Chemistry 2005 280 24 22925 22936 2-s2.0-20744440945 10.1074/jbc.M414635200 (Pubitemid 40853201)
15. Kotlo K. U., Yehiely F., Efimova E., Harasty H., Hesabi B., Shchors K., Einat P., Rozen A., Berent E., Deiss L. P., Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells. Oncogene 2003 22 6 797 806 2-s2.0-0037434737 10.1038/sj.onc.1206077 (Pubitemid 36255814)
16. Yenki P., Khodagholi F., Shaerzadeh F., Inhibition of phosphorylation of JNK suppresses Abeta-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus. Journal of Molecular Neuroscience. In press
17. Liu H., Dinkova-Kostova A. T., Talalay P., Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proceedings of the National Academy of Sciences of the United States of America 2008 105 41 15926 15931 2-s2.0-57349116768 10.1073/pnas.0808346105
18. Baird L., Dinkova-Kostova A. T., The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology 2011 85 4 241 272 2-s2.0-79954416526 10.1007/s00204-011-0674-5
19. Hayes J. D., McMahon M., Chowdhry S., Dinkova-Kostova A. T., Cancer chemoprevention mechanisms mediated through the keap1-Nrf2 pathway. Antioxidants and Redox Signaling 2010 13 11 1713 1748 2-s2.0-77958130983 10.1089/ars.2010.3221
20. Cullinan S. B., Gordan J. D., Jin J., Harper J. W., Diehl J. A., The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and Cellular Biology 2004 24 19 8477 8486 2-s2.0-4544294365 10.1128/MCB.24.19.8477-8486.2004 (Pubitemid 39245070)
21. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J. D., Yamamoto M., Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and Development 1999 13 1 76 86 2-s2.0-0032953192 (Pubitemid 29045117)
22. Dinkova-Kostova A. T., Holtzclaw W. D., Wakabayashi N., Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 2005 44 18 6889 6899 2-s2.0-18244377997 10.1021/bi047434h (Pubitemid 40632407)
23. Bloom D. A., Jaiswal A. K., Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. The Journal of Biological Chemistry 2003 278 45 44675 44682 2-s2.0-0242666198 10.1074/jbc.M307633200 (Pubitemid 37377224)
24. Numazawa S., Ishikawa M., Yoshida A., Tanaka S., Yoshida T., Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. American Journal of Physiology 2003 285 2 C334 C342 2-s2.0-0041742490 (Pubitemid 36917848)
25. Ramsey C. P., Glass C. A., Montgomery M. B., Lindl K. A., Ritson G. P., Chia L. A., Hamilton R. L., Chu C. T., Jordan-Sciutto K. L., Expression of Nrf2 in neurodegenerative diseases. Journal of Neuropathology and Experimental Neurology 2007 66 1 75 85 2-s2.0-33846073880 10.1097/nen.0b013e31802d6da9 (Pubitemid 46066791)
26. Sun Z., Wu T., Zhao F., Lau A., Birch C. M., Zhang D. D., KPNA6 (Importin α 7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Molecular and Cellular Biology 2011 31 9 1800 1811 2-s2.0-79955442831 10.1128/MCB.05036-11
27. Rada P., Rojo A. I., Chowdhry S., McMahon M., Hayes J. D., Cuadrado A., SCF/ β -TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Molecular and Cellular Biology 2011 31 6 1121 1133 2-s2.0-79952256187 10.1128/MCB.01204-10
28. Ramos-Gomez M., Kwak M. K., Dolan P. M., Itoh K., Yamamoto M., Talalay P., Kensler T. W., Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2001 98 6 3410 3415 2-s2.0-0035853157 10.1073/pnas.051618798 (Pubitemid 32220859)
29. Neymotin A., Calingasan N. Y., Wille E., Naseri N., Petri S., Damiano M., Liby K. T., Risingsong R., Sporn M., Beal M. F., Kiaei M., Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2011 51 1 88 96 2-s2.0-79957959973 10.1016/j.freeradbiomed.2011.03.027
30. Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E., Cole G. M., Phenolic anti-inflammatory antioxidant reversal of A β -induced cognitive deficits and neuropathology. Neurobiology of Aging 2001 22 6 993 1005 2-s2.0-0035686083 10.1016/S0197-4580(01)00300-1 (Pubitemid 34070638)
31. Kanninen K., Malm T. M., Jyrkkänen H. K., Goldsteins G., Keksa-Goldsteine V., Tanila H., Yamamoto M., Ylä-Herttuala S., Levonen A. L., Koistinaho J., Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Molecular and Cellular Neuroscience 2008 39 3 302 313 2-s2.0-53749088028 10.1016/j.mcn.2008.07.010
32. Dumont M., Wille E., Calingasan N. Y., Tampellini D., Williams C., Gouras G. K., Liby K., Sporn M., Flint Beal M., Lin M. T., Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry 2009 109 2 502 512 2-s2.0-62649115489 10.1111/j.1471-4159.2009.05970.x
33. Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H., Ylä-Herttuala S., Tanila H., Levonen A. L., Koistinaho M., Koistinaho J., Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2009 106 38 16505 16510 2-s2.0-70349482547 10.1073/pnas.0908397106
34. Abdel-Wahab M. H., Potential neuroprotective effect of t-butylhydroquinone against neurotoxicityinduced by 1-methyl-4-(2′- methylphenyl)-1,2,3,6- tetrahydropyridine (2′-methyl-MPTP) in mice. Journal of Biochemical and Molecular Toxicology 2005 19 1 32 41 2-s2.0-14644436461 10.1002/jbt.20053 (Pubitemid 40315389)
35. Yang L., Calingasan N. Y., Thomas B., Charturvedi R. K., Kiaei M., Wille E. J., Liby K. T., Williams C., Royce D., Risingson R., Musiek E. S., Morrow J. D., Sporn M., Beal M. F., Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE 2009 4 6, article e5757 2-s2.0-66749132810 10.1371/journal.pone.0005757
36. Chen P. C., Vargas M. R., Pani A. K., Smeyne R. J., Johnson D. A., Kan Y. W., Johnson J. A., Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2933 2938 2-s2.0-62449132771 10.1073/pnas.0813361106
37. Barone M. C., Sykiotis G. P., Bohmann D., Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. DMM Disease Models and Mechanisms 2011 4 5 701 707 2-s2.0-80052277569 10.1242/dmm.007575
38. Stack C., Ho D., Wille E., Calingasan N. Y., Williams C., Liby K., Sporn M., Dumont M., Beal M. F., Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine 2010 49 2 147 158 2-s2.0-77953537441 10.1016/j.freeradbiomed.2010.03. 017
39. Hickey M. A., Zhu C., Medvedeva V., Lerner R. P., Patassini S., Franich N. R., Maiti P., Frautschy S. A., Zeitlin S., Levine M. S., Chesselet M.-F., Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Molecular Neurodegeneration 2012 7 1, article 12 2-s2.0-84859189953 10.1186/1750-1326-7-12
40. Slocum S. L., Kensler T. W., Nrf2: control of sensitivity to carcinogens. Archives of Toxicology 2011 85 4 273 284 2-s2.0-79954424076 10.1007/s00204-011-0675-4
41. Blake D. J., Singh A., Kombairaju P., Malhotra D., Mariani T. J., Tuder R. M., Gabrielson E., Biswal S., Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. American Journal of Respiratory Cell and Molecular Biology 2010 42 5 524 536 2-s2.0-77951642473 10.1165/rcmb.2009-0054OC
42. Kraft A. D., Johnson D. A., Johnson J. A., Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. Journal of Neuroscience 2004 24 5 1101 1112 2-s2.0-0842304134 10.1523/JNEUROSCI.3817-03.2004 (Pubitemid 38177017)
43. Calkins M. J., Jakel R. J., Johnson D. A., Chan K., Yuen W. K., Johnson J. A., Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proceedings of the National Academy of Sciences of the United States of America 2005 102 1 244 249 2-s2.0-11844253848 10.1073/pnas.0408487101 (Pubitemid 40094460)
44. Pehar M., Vargas M. R., Robinson K. M., Cassina P., Díaz-Amarilla P. J., Hagen T. M., Radi R., Barbeito L., Beckman J. S., Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. Journal of Neuroscience 2007 27 29 7777 7785 2-s2.0-34447633192 10.1523/JNEUROSCI.0823-07. 2007 (Pubitemid 47093805)
45. Kirby J., Halligan E., Baptista M. J., Allen S., Heath P. R., Holden H., Barber S. C., Loynes C. A., Wood-Allum C. A., Lunec J., Shaw P. J., Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005 128 7 1686 1706 2-s2.0-21944454604 10.1093/brain/awh503 (Pubitemid 41373687)
46. Vargas M. R., Pehar M., Cassina P., Martínez-Palma L., Thompson J. A., Beckman J. S., Barbeito L., Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. The Journal of Biological Chemistry 2005 280 27 25571 25579 2-s2.0-21844474290 10.1074/jbc.M501920200 (Pubitemid 40962264)
47. Kraft A. D., Resch J. M., Johnson D. A., Johnson J. A., Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Experimental Neurology 2007 207 1 107 117 2-s2.0-34548287969 10.1016/j.expneurol.2007.05.026 (Pubitemid 47332487)
48. Sarlette A., Krampfl K., Grothe C., Neuhoff N. V., Dengler R., Petri S., Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology 2008 67 11 1055 1062 2-s2.0-58149232639 10.1097/NEN.0b013e31818b4906
49. Suh J. H., Shenvi S. V., Dixon B. M., Liu H., Jaiswal A. K., Liu R. M., Hagen T. M., Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proceedings of the National Academy of Sciences of the United States of America 2004 101 10 3381 3386 2-s2.0-1542723493 10.1073/pnas.0400282101 (Pubitemid 38338203)
50. Prochaska H. J., Santamaria A. B., Direct measurement of NAD(P)H: quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Analytical Biochemistry 1988 169 2 328 336 2-s2.0-0023930873 (Pubitemid 18081406)
51. Kwak M. K., Kensler T. W., Targeting NRF2 signaling for cancer chemoprevention. Toxicology and Applied Pharmacology 2010 244 1 66 76 2-s2.0-77649270763 10.1016/j.taap.2009.08.028
52. Liby K., Black C. C., Royce D. B., Williams C. R., Risingsong R., Yore M. M., Liu X., Honda T., Gribble G. W., Lamph W. W., Sporn T. A., Dmitrovsky E., Sporn M. B., The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics 2008 7 5 1251 1257 2-s2.0-49849104720 10.1158/1535-7163.MCT-08-0023
53. Ammal-Kaidery N., Banerjee R., Yang L., Smirnova N. A., Hushpulian D. M., Liby K. T., Williams C. R., Yamamoto M., Kensler T. W., Ratan R. R., Sporn M. B., Beal M. F., Gazaryan I. G., Thomas B., Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling. In press